Cargando…
Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer
SIMPLE SUMMARY: Pancreatic cancer is presently the fourth most common cause of cancer-related death. Treatment options and prognosis are poor. Therefore, new therapeutic approaches are urgently needed. Molecular targeting of the interleukin-6/glycoprotein-130/signal transducer and activator of trans...
Autores principales: | Hering, Nina A., Günzler, Emily, Arndt, Marco, Zibell, Miriam, Lauscher, Johannes C., Kreis, Martin E., Beyer, Katharina, Seeliger, Hendrik, Pozios, Ioannis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856922/ https://www.ncbi.nlm.nih.gov/pubmed/36672405 http://dx.doi.org/10.3390/cancers15020456 |
Ejemplares similares
-
Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144
por: Pozios, Ioannis, et al.
Publicado: (2022) -
Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling
por: Pozios, Ioannis, et al.
Publicado: (2020) -
Blockage of Cholinergic Signaling via Muscarinic Acetylcholine Receptor 3 Inhibits Tumor Growth in Human Colorectal Adenocarcinoma
por: Hering, Nina A., et al.
Publicado: (2021) -
Risk factors for upper and lower type prolonged postoperative ileus following surgery for Crohn’s disease
por: Pozios, Ioannis, et al.
Publicado: (2021) -
Impact of myopenia and myosteatosis on postoperative outcome and recurrence in Crohn’s disease
por: Pozios, Ioannis, et al.
Publicado: (2022)